Skip to main content

Outage notice:

We have restored nearly all systems affected by the global information outage, and welcome patients to visit our Patient Service Centers. To reschedule a missed appointment, please visit our online scheduling site.   


Identify the presence and activity of a high-risk HPV infection

  • While all FDA-approved HPV assays have similar, excellent sensitivity, Aptima® HPV mRNA testing provides superior specificity
  • Better specificity means fewer false positives
  • Fewer false positives can help reduce unnecessary procedures and reduce anxiety for patients1, 2


Aptima, along with Pap testing, has a combined sensitivity of over 99% for detecting cancer and high-grade cervical disease.3


With better specificity than HPV DNA testing, Aptima has been shown to reduce false positives and minimize unnecessary invasive procedures.3



Identifies high-risk HPV types of most concern, including 16, 18/45, most often associated with squamous cell carcinoma and adenocarcinoma.3

For more information

To set up testing, contact your sales representative or call 1.866.MYQUEST (1.866.697.8378).

You can also learn more about Aptima in our Test Directory.

Test Directory
  1. Sawaya GF, Kuppermann M. Identifying a “range of reasonable options” for cervical cancer screening. Obstet Gynecol. 2015;125(2):308-310. doi: 10.1097/AOG.0000000000000670
  2. Clad A, Reuschenbach M, Weinschenk J, Grote R, Rahmsdorf J, Freudenberg N. Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology. J Clin Microbiol. 2011;49(3):1071-1076. doi: 10.1128/JCM.01674-10
  3. Aptima HPV assay [package insert].

The Aptima HPV Assay detects E6/E7 viral mRNA from 14 high-risk types of human papillomavirus in cervical specimens (in ThinPrep® Pap Test vials containing PreservCyt® Solution and collected with broomtype or cytobrush/spatula devices). The test is indicated to screen women ≥21 years with ASCUS cytology to determine the need for colposcopy, and to screen women ≥30 years for high-risk HPV types. This information with cytology history, other risk factors, and guidelines may be used to manage patients. See for more details.

The assay is not a substitute for regular cervical cytology screening. The results of this test are not intended to prevent women from proceeding to colposcopy. The assay has not been evaluated for managing HPV vaccinated women, women with prior ablative or excisional therapy, hysterectomy, who are pregnant, or have other risk factors. Aptima and other associated logos are registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States, and/or other countries.

Co-testing solutions for

cervical cancer

Learn more about how Pap and HPV mRNA

testing work together to provide early

detection of cervical cancer.

Download Brochure